Compare Archer-Daniels-Midland Co (ADM) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Novavax Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.67 (market cap $38.78B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Archer-Daniels-Midland Co is far larger — about 29.6× Novavax Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ADM | NVAX | |
|---|---|---|
Market Cap | $38.78B | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $11.19 |
52-Week Low | $56.00 | $6.22 |
Enterprise Value | $47.03B | $889.30M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.72, down 0.96% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 21.98 and P/S of 0.48, while revenue for 2025 was $80.27B. Recent news highlights growth in biofuels and crushing margins, with the company raising its 2026 earnings outlook after a strong Q2.
The outlook is positive, supported by raised guidance and operational strength, but risks include execution challenges and margin pressures. Analysts maintain a consensus price target of $88.00, indicating potential upside from current levels amid a predominantly hold rating sentiment.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
